Soligenix ( (SNGX)) has shared an announcement. On July 31, 2025, Soligenix announced the completion of its Phase 2a proof of concept study for SGX945 (dusquetide) in treating Behçet’s Disease, ...

A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry. | The Fierce Biotech Fundraising Tracker records ...